

2020 sildenafil 20 mg (generic Revatio[®] only) Tablet Prior Authorization Request

Page 1 of 2 (You must complete all pages.)

Fax completed form to: 1-800-408-2386 For urgent requests, please call: 1-800-414-2386

Coverage Criteria:

- Medication is covered on plan when prescribed for:
 - Pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening, when PAH has been confirmed by right heart catheterization

For NEW starts, the patient must have ALL the following:

- 1. Pretreatment mean pulmonary arterial pressure is greater than or equal to 25 mmHg
- 2. Pretreatment pulmonary capillary wedge pressure is less than or equal to 15 mmHg
- 3. Pretreatment pulmonary vascular resistance is greater than 3 Wood units

Authorization duration: Through end of plan contract year

| Patient information | | Prescriber info | Prescriber information | | | | |
|--|---|-------------------------|--|-----------------|----------------------------|--|--|
| Patient name Patient insurance ID number Patient address, city, state, ZIP | | Today's date | Today's date Physician Physician name | | n specialty | | |
| | | Physician name | | | NPI/DEA number | | |
| | | Physician addre | Physician address, city, state, ZIP | | | | |
| Patient home telephone number | | M.D. office tele | M.D. office telephone number | | | | |
| Gender ☐ Male ☐ Female | Patient date of birth | M.D. office fax | M.D. office fax number | | | | |
| Diagnosis and medical informa | ation | | | | | | |
| Medication requested | | | Frequency | | | | |
| sildenafil (generic Re | vatio) 20mg tablet | | | | | | |
| New prescription OR date therapy initiated | | Quantity | Day s | upply | Expected length of therapy | | |
| Diagnosis (Please check all bo | exes that apply and include all | l office notes supporti | ng diagnosi | is.) | | | |
| ☐ Pulmonary arterial hypertensi☐ Other (ICD-10 codes): | on (WHO Group I) in adults to i | mprove exercise ability | and delay cli | inical worsenir | ng | | |
| Please check all boxes that ap | ply: | | | | | | |
| 1. Patient is stable on curre | nt drug(s) and/or current qua | ntity, and therapy cha | nge would li | ikely result in | adverse clinical outcomes. | | |
| 2. All covered Part D drugs drug and/or would likely | on any tier of the plan's form have adverse effects for the e | | effective for | r the enrollee | as the requested formulary | | |
| | fil 20mg tablet ONLY be used fo f pulmonary arterial hypertensio | | | (ED) in a patie | ent that does NOT have a | | |

(continued on page 2)

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. If you received this transmission in error, please notify us immediately by telephone at 1-800-414-2386.



Page 2 of 2

| ΡI | lease check all box | oo mat appiy (oommaca). | | | |
|--------------------|--|--|--|---|---|
| 4. | For the diagnosis | of WHO Group I pulmonary | arterial hypertension (PAH): Pleas | se complete this section. | |
| 1 | ☐ Yes ☐ No | Was the diagnosis of pulmona | ary arterial hypertension (WHO Grou | p I) confirmed by right heart catheterization? | |
| | ☐ Yes ☐ No | Was the pretreatment mean p Was the pretreatment pulmor | pulmonary arterial pressure greater th nary capillary wedge pressure less tha nary vascular resistance greater than | an or equal to 15 mmHg? | |
| | Please explain why should include spec | your patient should be consid | not met and why patient should be exe | ard requirements listed above. ting the plan's suggested PA criteria. Statement empt from meeting this requirement. (Please note any | y |
| | | | | | |
| | | | | | |
| 5. | | The quantity limit for silden (quantity limit exception)? | afil 20mg tablet is 90 tablets per 30 | days. Does patient require higher dosage | |
| | | | uested: per 30 days | OR quantity per day | |
| | ☐ The number | | | drug has been ineffective in the treatment of the | |
| | ☐ The number medical ar | er of doses available under th | | drug, based on both sound clinical evidence and cteristics of the enrollee, and known characteristics of ctiveness or patient compliance. | : |
| | | | | | |
| 6. | ☐ Please list all m | nedications the patient has t | tried specific to the diagnosis and | specify below. | |
| Г | | nedications the patient has t | tried specific to the diagnosis and s | · · |] |
| Г | | - | | specify below. THERAPEUTIC OUTCOME | |
| Г | | - | | · · | |
| Г | | - | | · · | |
| Г | | - | | · · | |
| H | CURRENT/PAST M | IEDICATIONS USED | | · · | |
| H | Other supportin | ng information on requests require prescribe | DATES OF TREATMENT r supporting statements. Additionally | · · | |
| H | Other supporting *NOTE: All exception any other utilization | ng information on requests require prescribe | DATES OF TREATMENT r supporting statements. Additionally | THERAPEUTIC OUTCOME , requests that are subject to prior authorization (or | |
| H | Other supporting *NOTE: All exception any other utilization | ng information on requests require prescribe | DATES OF TREATMENT r supporting statements. Additionally | THERAPEUTIC OUTCOME , requests that are subject to prior authorization (or | - |
| H | Other supporting *NOTE: All exception any other utilization | ng information on requests require prescribe | DATES OF TREATMENT r supporting statements. Additionally | THERAPEUTIC OUTCOME , requests that are subject to prior authorization (or | - |
| H | Other supporting *NOTE: All exception any other utilization | ng information on requests require prescribe | DATES OF TREATMENT r supporting statements. Additionally | THERAPEUTIC OUTCOME , requests that are subject to prior authorization (or | - |
| 7. I aa fe m d o | Other supporting *NOTE: All exception any other utilization for your request. attest that the medicand that documentation ederal regulatory againsterial to a claim ultidamages under both obtained patient considerations. | ng information on requests require prescribe n management requirement), on supporting this information ency. I understand that any p timately paid by the United Sta the federal and state False C | r supporting statements. Additionally may require supporting information. In the second secon | THERAPEUTIC OUTCOME , requests that are subject to prior authorization (or | e |
| 7. I aa fe m d o A | Other supporting *NOTE: All exception any other utilization for your request. attest that the medicand that documentation ederal regulatory againsterial to a claim ultidamages under both obtained patient considerations. | requested is medically represent that any partial paid by the United State federal and state False Cleant as required under application and state re-disclosure | r supporting statements. Additionally may require supporting information. In the second secon | THERAPEUTIC OUTCOME , requests that are subject to prior authorization (or Please attach supporting information, as necessary, test that the information provided is accurate and true by the health plan sponsor, or, if applicable, a state or es to be made a false record or statement that is ment may be subject to civil penalties and treble 729-3733. By signing this form, I represent that I have | e |

Fax Confidentiality Notice: The information contained in this transmission is confidential, proprietary or privileged and may be subject to protection under the law, including the Health Insurance Portability and Accountability Act (HIPAA). The message is intended for the sole use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are notified that any use, distribution or copying of the attached material is strictly prohibited and may subject you to criminal or civil penalties. If you received this transmission in error, please notify us immediately by telephone at 1-800-414-2386.